EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

SARS-CoV-2 Mac1 is required for IFN antagonism and efficient virus replication in cell culture and in mice

Yousef M Alhammad, Srivatsan Parthasarathy iD, Roshan Ghimire iD, Catherine M Kerr iD, Joseph J O'Connor, Jessica J Pfannenstiel, Debarati Chanda, Caden A Miller, Nathalie Baumlin, Matthias Salathe iD, Robert L Unckless iD, Sonia Zuñiga iD und 4 weitere

Proceedings of the National Academy of Sciences · 29.08.2023 · 120 (35)

DOI: 10.1073/pnas.2302083120 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, online erschienen am 22.08.2023. Verfasst von Yousef M Alhammad und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Biosciences, University of Kansas, Lawrence, KS 66047. Hauptthemen laut MEDLINE: COVID-19, Middle East Respiratory Syndrome Coronavirus, Murine hepatitis virus. Die Arbeit wurde bisher 66-mal zitiert (Crossref) und nennt 72 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIGMS NIH HHS, NIAID NIH HHS, NHLBI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Several coronavirus (CoV) encoded proteins are being evaluated as targets for antiviral therapies for COVID-19. Included in these drug targets is the conserved macrodomain, or Mac1, an ADP-ribosylhydrolase and ADP-ribose binding protein encoded as a small domain at the N terminus of nonstructural protein 3. Utilizing point mutant recombinant viruses, Mac1 was shown to be critical for both murine hepatitis virus (MHV) and severe acute respiratory syndrome (SARS)-CoV virulence. However, as a potential drug target, it is imperative to understand how a complete Mac1 deletion impacts the replication and pathogenesis of different CoVs. To this end, we created recombinant bacterial artificial chromosomes (BACs) containing complete Mac1 deletions (ΔMac1) in MHV, MERS-CoV, and SARS-CoV-2. While we were unable to recover infectious virus from MHV or MERS-CoV ΔMac1 BACs, SARS-CoV-2 ΔMac1 was readily recovered from BAC transfection, indicating a stark difference in the requirement for Mac1 between different CoVs. Furthermore, SARS-CoV-2 ΔMac1 replicated at or near wild-type levels in multiple cell lines susceptible to infection. However, in a mouse model of severe infection, ΔMac1 was quickly cleared causing minimal pathology without any morbidity. ΔMac1 SARS-CoV-2 induced increased levels of interferon (IFN) and IFN-stimulated gene expression in cell culture and mice, indicating that Mac1 blocks IFN responses which may contribute to its attenuation. ΔMac1 infection also led to a stark reduction in inflammatory monocytes and neutrophils. These results demonstrate that Mac1 only minimally impacts SARS-CoV-2 replication, unlike MHV and MERS-CoV, but is required for SARS-CoV-2 pathogenesis and is a unique antiviral drug target.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19Middle East Respiratory Syndrome CoronavirusMurine hepatitis virusAnimalsMiceSARS-CoV-2Cell Culture TechniquesCell LineAntiviral Agents

Stichwörter der Autor:innen

ADP-ribosylationSARS-CoV-2coronavirusinterferonmacrodomain

Substanzen

Antiviral Agents

Autor:innen und Institutionen

  • Department of Molecular Biosciences, University of Kansas, Lawrence, KS 66047.
  • Department of Veterinary Pathobiology, Oklahoma State University, Stillwater, OK 74078.
  • Department of Internal Medicine, University of Kansas Medical Center, Kansas City, KS 66160.
  • Department of Molecular and Cell Biology, National Center of Biotechnology, Madrid 28049, Spain.

ORCID-Profile: Srivatsan Parthasarathy, Roshan Ghimire, Catherine M Kerr, Matthias Salathe, Robert L Unckless, Sonia Zuñiga, Luis Enjuanes, Anthony R Fehr

Förderung

  • NIGMS NIH HHS
  • NIAID NIH HHS
  • NHLBI NIH HHS
  • HHS | NIH | National Institute of General Medical Sciences
  • Division of Intramural Research, National Institute of Allergy and Infectious Diseases
  • HHS | NIH | National Institute of Allergy and Infectious Diseases
  • National Science Foundation
  • European Commission

Zitieren

APA

Alhammad, Y. M., Parthasarathy, S., Ghimire, R., Kerr, C. M., O'Connor, J. J., Pfannenstiel, J. J., Chanda, D., Miller, C. A., Baumlin, N., Salathe, M., Unckless, R. L., Zuñiga, S., Enjuanes, L., More, S., Channappanavar, R., & Fehr, A. R. (2023). SARS-CoV-2 Mac1 is required for IFN antagonism and efficient virus replication in cell culture and in mice. Proceedings of the National Academy of Sciences, 120(35). https://doi.org/10.1073/pnas.2302083120

Vancouver

Alhammad YM, Parthasarathy S, Ghimire R, Kerr CM, O'Connor JJ, Pfannenstiel JJ, et al. SARS-CoV-2 Mac1 is required for IFN antagonism and efficient virus replication in cell culture and in mice. Proceedings of the National Academy of Sciences. 2023;120(35). doi:10.1073/pnas.2302083120

BibTeX
@article{Alhammad2023,
  author = {Alhammad, Yousef M and Parthasarathy, Srivatsan and Ghimire, Roshan and Kerr, Catherine M and O'Connor, Joseph J and Pfannenstiel, Jessica J and Chanda, Debarati and Miller, Caden A and Baumlin, Nathalie and Salathe, Matthias and Unckless, Robert L and Zuñiga, Sonia and Enjuanes, Luis and More, Sunil and Channappanavar, Rudragouda and Fehr, Anthony R},
  title = {SARS-CoV-2 Mac1 is required for IFN antagonism and efficient virus replication in cell culture and in mice},
  journal = {Proceedings of the National Academy of Sciences},
  year = {2023},
  volume = {120},
  number = {35},
  doi = {10.1073/pnas.2302083120}
}
Kostenlos starten →